ATyr Pharma is stepping up its preparations to launch a steroid-sparing drug with the appointment of a commercial head who previously helped ChemoCentryx communicate a similar value proposition en ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

Has Atyr Pharma (ATYR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Atyr Pharma is a member of the Medical sector. This group ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company with a market capitalization of $310 million, announced the appointment of Dalia R. Rayes as the new Head of ...

Atyr PHARMA Stock Down 2.1 % Shares of NASDAQ:ATYR opened at $3.68 on Friday. The company has a market cap of $327.00 million, a price-to-earnings ratio of -3.91 and a beta of 0.98. The firm’s ...

NASDAQ ATYR opened at $3.10 on Tuesday. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66. The company has a 50-day simple moving average of $3.66 and a 200 day simple moving ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the“Company”), a clinical stage ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $15 million in its fourth quarter. The San Diego-based company said it had a loss of 18 cents per share.